TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

Study identifier:D5180C00034

ClinicalTrials.gov identifier:NCT05729711

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

TEZSPIRE Subcutaneous Injection 210mg Specific use-results study (Long term) in patients with Bronchial asthma.

Medical condition

Bronchial asthma (only the patients with severe or intractable bronchial asthma which could not be controlled with the existing therapy)

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

400

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 04 Apr 2023
Estimated Primary Completion Date: 16 Nov 2029
Estimated Study Completion Date: 16 Nov 2029

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria